Barclays PLC Acquires 104,310 Shares of Accuray Incorporated (NASDAQ:ARAY)

Barclays PLC boosted its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 97.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 210,819 shares of the medical equipment provider’s stock after purchasing an additional 104,310 shares during the quarter. Barclays PLC owned about 0.21% of Accuray worth $380,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARAY. Armistice Capital LLC bought a new stake in shares of Accuray in the second quarter valued at approximately $910,000. Foundry Partners LLC raised its stake in Accuray by 51.3% during the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares during the last quarter. State Street Corp boosted its holdings in Accuray by 3.8% in the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after purchasing an additional 70,008 shares during the period. BNP Paribas Financial Markets grew its position in Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock worth $263,000 after purchasing an additional 138,022 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after purchasing an additional 230,695 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Trading Up 6.2 %

Shares of ARAY stock opened at $2.07 on Friday. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63. The firm has a fifty day moving average of $1.93 and a 200-day moving average of $1.89. Accuray Incorporated has a 52-week low of $1.40 and a 52-week high of $2.99. The stock has a market cap of $208.17 million, a price-to-earnings ratio of -12.18 and a beta of 1.47.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. During the same quarter last year, the company earned ($0.03) earnings per share. On average, equities research analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.